[Clinical studies of intravenous drip infusion of micronomicin. Urinary tract infections].
There is a growing tendency that aminoglycosides are used by intravenous drip infusion. Micronomicin sulfate (MCR) is a new aminoglycoside antibiotic and its mild nephrotoxicity and ototoxicity demonstrated in animals set us to perform clinical studies, in which 22 institutions in Japan used this antibiotic by intravenous drip infusion for the treatment of urinary tract infections and reached the following conclusions: The response rate in complicated urinary tract infections was 60.6% when daily 240 mg was administered in 2 doses and 52.9% when daily 360 mg was administered in 2 doses or 3 doses. Intravenous drip infusion of daily 240 to 360 mg of MCR did not present safety problems. Intravenous drip infusion of MCR is therefore considered to be of clinical interests in urinary tract infections.
D000328:Adult; D000368:Aged; D000617:Aminoglycosides / Q000008:administration & dosage / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005260:Female; D005839:Gentamicins; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000382:microbiology
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D005839:Gentamicins; C037545:micronomicin